{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T05:43:56Z","timestamp":1793598236640,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016915","name":"Inventiva SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007698","name":"University of Florida","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007698","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jhep.2024.12.045","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T02:15:17Z","timestamp":1736907317000},"page":"979-991","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":96,"title":["Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD"],"prefix":"10.1016","volume":"82","author":[{"given":"Diana","family":"Barb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srilaxmi","family":"Kalavalapalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eddison","family":"Godinez Leiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5570-4396","authenticated-orcid":false,"given":"Fernando","family":"Bril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Huot-Marchand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucile","family":"Dzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5957-0313","authenticated-orcid":false,"given":"Jens T.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Junien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Broqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9192-9442","authenticated-orcid":false,"given":"Andrea Ortiz","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romina","family":"Lomonaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3314-4727","authenticated-orcid":false,"given":"Jean-Louis","family":"Abitbol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Cooreman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8629-418X","authenticated-orcid":false,"given":"Kenneth","family":"Cusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2024.12.045_bib1","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1053\/j.gastro.2012.02.003","article-title":"Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications","volume":"142","author":"Cusi","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.12.045_bib2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.cld.2023.01.002","article-title":"Metabolic syndrome and its association with nonalcoholic steatohepatitis","volume":"27","author":"Bril","year":"2023","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jhep.2024.12.045_bib3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2337\/dsi23-0013","article-title":"Role of insulin resistance in the development of nonalcoholic fatty liver disease in people with type 2 diabetes: from bench to patient care","volume":"37","author":"Nogueira","year":"2024","journal-title":"Diabetes Spectr"},{"key":"10.1016\/j.jhep.2024.12.045_bib4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2337\/dsi23-0010","article-title":"Understanding the burden of nonalcoholic fatty liver disease: time for action","volume":"37","author":"Younossi","year":"2024","journal-title":"Diabetes Spectr"},{"key":"10.1016\/j.jhep.2024.12.045_bib5","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1002\/hep.25539","article-title":"Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease","volume":"55","author":"Lomonaco","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.12.045_bib6","doi-asserted-by":"crossref","first-page":"632","DOI":"10.2337\/dc15-1876","article-title":"Metabolic impact of nonalcoholic steatohepatitis in obese patients with type 2 diabetes","volume":"39","author":"Lomonaco","year":"2016","journal-title":"Diabetes Care"},{"issue":"Suppl 2","key":"10.1016\/j.jhep.2024.12.045_bib7","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/dom.14484","article-title":"Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications","volume":"24","author":"Byrne","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jhep.2024.12.045_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2021-002517","article-title":"Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK","volume":"10","author":"Weiss","year":"2022","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.jhep.2024.12.045_bib9","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"issue":"Supplement_1","key":"10.1016\/j.jhep.2024.12.045_bib10","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.2337\/dc24-S004","article-title":"4. Comprehensive medical evaluation and assessment of comorbidities: standards of care in diabetes\u20142024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jhep.2024.12.045_bib11","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.12.045_bib12","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jhep.2020.04.025","article-title":"Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages","volume":"73","author":"Lefere","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.12.045_bib13","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A Randomized, Controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2024.12.045_bib14","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1038\/s41467-024-47919-9","article-title":"The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis","volume":"15","author":"Cooreman","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2024.12.045_bib15","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/hep.28985","article-title":"Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease","volume":"65","author":"Bril","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.12.045_bib16","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/dom.13584","article-title":"Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes","volume":"21","author":"Cusi","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jhep.2024.12.045_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214921","article-title":"Repeatability and reproducibility of multiparametric magnetic resonance imaging of the liver","volume":"14","author":"Bachtiar","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2024.12.045_bib18","doi-asserted-by":"crossref","first-page":"E1125","DOI":"10.1210\/jc.2015-1587","article-title":"Hepatic de novo lipogenesis in obese youth Is modulated by a common variant in the GCKR gene","volume":"100","author":"Santoro","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jhep.2024.12.045_bib19","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1053\/j.gastro.2013.11.049","article-title":"Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease","volume":"146","author":"Lambert","year":"2014","journal-title":"Gastroenterology"},{"issue":"20","key":"10.1016\/j.jhep.2024.12.045_bib20","doi-asserted-by":"crossref","first-page":"4734","DOI":"10.1021\/ac990724x","article-title":"Quantitation of monosaccharide isotopic enrichment in physiologic fluids by electron ionization or negative chemical ionization GC\/MS using di-O-isopropylidene derivatives","volume":"71","author":"Hachey","year":"1999","journal-title":"Anal Chem"},{"key":"10.1016\/j.jhep.2024.12.045_bib21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1210\/clinem\/dgab578","article-title":"The emerging role of glucagon-like peptide-1 receptor agonists for the management of NAFLD","volume":"107","author":"Patel","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jhep.2024.12.045_bib22","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2337\/dsi23-0012","article-title":"Pharmacological approaches to nonalcoholic fatty liver disease: current and future therapies","volume":"37","author":"Genua","year":"2024","journal-title":"Diabetes Spectr"},{"key":"10.1016\/j.jhep.2024.12.045_bib23","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo controlled trial of pioglitazone in patients with non-alcoholic steatohepatitis (NASH)","volume":"355","author":"Belfort","year":"2006","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jhep.2024.12.045_bib24","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2024.12.045_bib25","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2337\/dc19-0167","article-title":"Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: a randomized controlled trial","volume":"42","author":"Bril","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jhep.2024.12.045_bib26","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1002\/oby.24130","article-title":"Obesity increases the risk of hepatic fibrosis in young adults with type 2 diabetes mellitus: the need to screen","volume":"32","author":"Sharma","year":"2024","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.jhep.2024.12.045_bib27","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1111\/liv.15005","article-title":"PPAR-\u03b3-induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH","volume":"41","author":"Gastaldelli","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2024.12.045_bib28","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1038\/oby.2011.152","article-title":"Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes","volume":"19","author":"Sathyanarayana","year":"2011","journal-title":"Obesity"},{"key":"10.1016\/j.jhep.2024.12.045_bib29","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2213-8587(17)30092-X","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial","volume":"5","author":"Ahr\u00e9n","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jhep.2024.12.045_bib30","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/dom.14650","article-title":"Combination therapy with pioglitazone\/exenatide\/metformin reduces the prevalence of hepatic fibrosis and steatosis: the efficacy and durability of initial combination therapy for type 2 diabetes (EDICT)","volume":"24","author":"Lavynenko","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jhep.2024.12.045_bib31","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.clinthera.2015.05.511","article-title":"Empagliflozin as add-on therapy to pioglitazone with or without metformin in patients with type 2 diabetes mellitus","volume":"37","author":"Kovacs","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.jhep.2024.12.045_bib32","article-title":"Benefits of combining SGLT2 inhibitors and pioglitazone on risk of MASH in type 2 diabetes-A real-world study","volume":"5","author":"Lee","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jhep.2024.12.045_bib33","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1111\/dom.15576","article-title":"Effect of combination pioglitazone with sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists on outcomes in type 2 diabetes: a systematic review, meta-analysis, and real-world study from an international federated database","volume":"26","author":"Anson","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jhep.2024.12.045_bib34","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1097\/HEP.0000000000000263","article-title":"Diabetes and cirrhosis: current concepts on diagnosis and management","volume":"77","author":"Castera","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.12.045_bib35","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1210\/jc.2015-1966","article-title":"High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels","volume":"100","author":"Portillo-Sanchez","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jhep.2024.12.045_bib36","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1002\/oby.23263","article-title":"Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease","volume":"29","author":"Barb","year":"2021","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.jhep.2024.12.045_bib37","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.2337\/dc22-2048","article-title":"High prevalence of NASH and advanced fibrosis in type 2 diabetes: a prospective study of 330 outpatients undergoing liver biopsies for elevated ALT, using a low threshold","volume":"46","author":"Castera","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jhep.2024.12.045_bib38","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/hep.31806","article-title":"Glycemic control predicts severity of hepatocyte ballooning and hepatic fibrosis in nonalcoholic fatty liver disease","volume":"74","author":"Alexopoulos","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.12.045_bib39","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2337\/dc20-1997","article-title":"Advanced liver fibrosis Is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening","volume":"44","author":"Lomonaco","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jhep.2024.12.045_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2023.117237","article-title":"Hepatic fatty acid and glucose handling in metabolic disease: potential impact on cardiovascular disease risk","volume":"394","author":"Westcott","year":"2024","journal-title":"Atherosclerosis"},{"issue":"12","key":"10.1016\/j.jhep.2024.12.045_bib41","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1194\/jlr.M800165-JLR200","article-title":"A pilot study of the effects of pioglitazone and rosiglitazone on de novo lipogenesis in type 2 diabetes","volume":"49","author":"Beysen","year":"2008","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jhep.2024.12.045_bib42","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ajcnut.2024.06.006","article-title":"The impact of short-term eucaloric low- and high-carbohydrate diets on liver triacylglycerol content in males with overweight and obesity: a randomized crossover study","volume":"120","author":"London","year":"2024","journal-title":"Am J Clin Nutr"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827825000029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827825000029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T03:01:12Z","timestamp":1773457272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827825000029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0168827825000029"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2024.12.045","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2024.12.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}